Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Date:1/25/2008

risk of heart attack and stroke. The niacin receptor, a G protein-coupled receptor, or GPCR, is believed to have potential in regulating plasma lipid profiles, including HDL.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic and other potential of niacin receptor agonists; the results of the Phase 1 clinical trial of a second generation niacin receptor agonist; the continuation and progress of the collaboration between Merck and Arena and the activities and program thereunder; the niacin receptor's potential in regulating plasma lipid profiles; the potential of drugs that influence HDL cholesterol to provide clinical benefits to patients; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
2. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
3. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
4. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
9. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
10. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
11. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 /PRNewswire/ -- Capitalizing ... sciences industry and an active venture capital market, ... State Teachers Retirement Fund, Indiana University, Purdue University, ... Foundation, and Credit Suisse today announced the establishment ... capital fund of funds. ,, Organized through BioCrossroads, ...
(Date:12/16/2009)... pursuant to Special Protocol Assessment with the ... Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... "Company"), a global biopharmaceutical company focused on ... initiation, by its partner Keryx Biopharmaceuticals Inc. ... registration clinical trial for perifosine (KRX-0401), the ...
(Date:12/16/2009)... its 23rd Annual Technical Conference & Exhibition on March 22-25, 2010 ... impact the separation society and reach out to even more experts ... AFS Annual Technical Conference will be co-located with the 2010 AIChE ... ... December 16, 2009 -- The American Filtration and Separations Society will ...
(Date:12/15/2009)... Sky One,Medical, Inc. ("China Sky One Medical" or ... integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has 30 medicines that will be ... Medical Insurance, Industrial Injury Insurance,and Maternity Insurance Medicine ... medicines treat a variety of common ailments and ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5American Filtration and Separations Society to Hold 23nd Annual Technical Conference 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 3American Filtration and Separations Society to Hold 23nd Annual Technical Conference 4China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3
... , , , , , , ... , 2 , Precautions and warnings , ... Materials , , , 3.1, ... 3.2, Materials required but not supplied , , ...
... , , , PLG can be used in small and large scale protocols ... given here works with E. coli cultures grown for 1214 , hours in ... ml Terrific Broth. , , , ... at room , temperature. , ...
... , Isolation of Coxiella Burnetii Genomic DNA from Goat ... Blood Mini Kit , , , , , ... INRA centre of TOURS, Unit de Pathologie Infectieuse et Immunologie, , ... 0247427779, e-mail: bouvery@tours.inra.fr , , , , , ...
Other Biology Technology:TripleMaster PCR System 2TripleMaster PCR System 3TripleMaster PCR System 4TripleMaster PCR System 5TripleMaster PCR System 6TripleMaster PCR System 7TripleMaster PCR System 8TripleMaster PCR System 9TripleMaster PCR System 10TripleMaster PCR System 11TripleMaster PCR System 12TripleMaster PCR System 13TripleMaster PCR System 14TripleMaster PCR System 15TripleMaster PCR System 16TripleMaster PCR System 17TripleMaster PCR System 18TripleMaster PCR System 19TripleMaster PCR System 20Basic Plasmid DNA Isolation Protocol 2EppendorfPerfect gDNA Blood Mini Kit 2EppendorfPerfect gDNA Blood Mini Kit 3EppendorfPerfect gDNA Blood Mini Kit 4EppendorfPerfect gDNA Blood Mini Kit 5
(Date:12/16/2009)... Maryland School of Medicine researcher will lead the coordinating ... scientists in the field of stem cell research. Michael ... was chosen by the National Heart, Lung and Blood ... of national experts, which will be called the NHLBI ... funded by a $30 million grant over seven years. ...
(Date:12/16/2009)... and PALM HARBOR, Fla., Dec. 2 /PRNewswire-FirstCall/ ... Board: CICI), a leading supplier of electronic ... the financial industry* and the recognized leader** ... Inc. ("Docubase"), a leading International Electronic Document ... they have entered an agreement to provide ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... identification solutions, today announced that SC Magazine, ... publications, named BIO-key International the 2009 Innovator ... sub-category Biometrics. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ... editor, SC Magazine, "Biometric providers have been ...
Breaking Biology News(10 mins):University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3FDA Takes Action Against Seafood Processing Company Executives 61329 1FDA Takes Action Against Seafood Processing Company Executives 61329 2Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Quantros Announces Partnership With Hospital Accreditation Agency DNV 6260 1Quantros Announces Partnership With Hospital Accreditation Agency DNV 6260 2
... VA. The Office of Naval Research (ONR) has ... U.S. Navy,s 2009 Young Investigator Program (YIP). , ... young minds in science, technology, engineering and mathematics," says ... investments in initiatives like the Young Investigator Program, ONR ...
... lateral sclerosis (ALS) is a fatal disease that damages ... disease causes progressive paralysis of voluntary muscles and often ... Gehrig,s disease) was discovered over a century ago, neither ... several mechanisms seem to play a role in its ...
... NEW ORLEANSNo one doubts that mothers especially pregnant ... And while the benefits of exercise for these women ... mothers do not exercise. A survey examining daily activities ... a larger study looking at the effect of maternal ...
Other Biology News:ONR announces 2009 Young Investigator Award recipients 2Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease 2Caffeine appears to be beneficial in males -- but not females -- with Lou Gehrig's disease 3Differences among exercisers and nonexercisers during pregnancy 2Differences among exercisers and nonexercisers during pregnancy 3
Request Info...
... a clone of the human Topoisomerase II gene. ... the topological state of nucleic acids by passing ... which generates a separate DNA helix (1,2) . ... mechanism, the enzyme can relax negatively or positively ...
Request Info...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
Biology Products: